Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At the foundation of that achievement sits a network of domestic generic and OTC manufacturers, several of them family-owned businesses now approaching their centenary, that together supply a significant share of the generics market that accounts for roughly 70 percent of all prescriptions written in the country.
Yet the companies that built this foundation are under growing stress. Pricing pressures are putting their traditional business models under threat, forcing them towards a more modern, diversified, and international future.
“Domestic pharmaceutical manufacturers play a crucial role within Taiwan’s healthcare system,” says Sen Kuei Yeh, the second-generation chairman of Ta Fong Pharmaceutical. “Established local companies are deeply integrated into the domestic market, ensuring the stable supply of essential medicines, reinforcing supply chain resilience, and supporting national healthcare security,” adds Yeh, whose firm has a marketed portfolio of over 200 products in Taiwan and also boasts the island’s only production line for female hormone injectables.
That resilience has taken on new strategic importance for the government. A cabinet-approved medical resilience programme, launched in 2026 with around USD 750 million allocated over four years, is directing new investment into domestic manufacturing capacity; a recognition that supply chain security cannot be taken for granted.
“For many years, domestic pharmaceutical companies were not a primary focus, as supply was largely stable and supported by imports,” explains Alexander Lin, the fourth generation to lead the company now known as Syntromed (formerly Chung Mei). “COVID-19 exposed structural vulnerabilities in global supply chains and prompted a reassessment of these assumptions.”
Founded in 1936 and historically focused on commercialisation, Syntromed is moving into the production space, with a continuous manufacturing facility for oral solid dosage forms in development. Lin continues, “The pharmaceutical resilience programme creates a meaningful opportunity for us to move beyond commercialisation and play a more active role in local production and supply.”
For companies like Syntromed, these new operations are being built on solid foundations. “Taiwan’s generic industry has a lot of strengths,” notes Tiffany Chen, chair of the Taiwan Generic Pharmaceutical Association (TGPA). “These include strong regulatory governance, consistent manufacturing quality, and a longstanding commitment to patient safety, all of which underpin both public trust and a growing international credibility.”
Pricing Pressures & Diversification
However, every year, the razor-thin margins under which these companies operate are contracting further, rendering existing business models increasingly difficult to sustain. “The annual downward adjustment of reimbursement prices is relentless, and managing that pressure is a constant discipline,” states Susan Liao, a second-generation leader, whose family firm Everest Pharmaceutical Industrial specialises in pellet drug delivery systems. “For some of our products, the price has already reached a floor where further reductions have little practical impact – it simply cannot go lower,” she adds.
“The environment is genuinely challenging,” admits Yeh, whose company Ta Fong is now exploring contract development and manufacturing (CDMO), original equipment manufacturing (OEM), and original design manufacturing (ODM) partnership models
“Under the national health insurance system, regular price adjustment mechanisms are designed to ensure the long-term sustainability of healthcare spending, but they also exert sustained downward pressure on pharmaceutical manufacturers – narrowing profit margins and constraining the capacity for long-term investment,” he states.
Syntromed’s Lin agrees, noting that, “The traditional model, largely centred on generics and replication, inevitably leads to price-driven competition … If we continue to rely on the same products, over time, we will ultimately compete only on price and service, which is not sustainable in the long-term.”
For Lin, this has meant moving towards “a more consumer-driven approach to product development,” using structured feedback to identify unmet needs and design targeted solutions. He notes that “This is already shaping our expansion into areas such as cholesterol management and preventive health, while also allowing us to extend into adjacent categories, including health supplements and selected medical devices, often through collaboration with external partners.”
Beyond these fields, Syntromed is also looking into animal health and even innovative drug development, having licensed a botanical candidate for the treatment of melanoma from Taiwan’s Development Center for Biotechnology back in 2017.
Health supplements are also a more recent priority for Everest, where Liao sees “a clear growth opportunity.” She explains that the firm’s expertise in pellet delivery has plenty of applications in the supplements space. “The R&D challenges we have already solved in pharmaceuticals – enteric release, sustained action, poor bioavailability, formulation stability – translate directly into high-end nutraceutical innovation, and pellet technology enables versatile formats such as granules and functional spheres that go well beyond what standard capsules or tablets can offer.”
Liao continues, “The regulatory environment for health supplements is also far more flexible and development-friendly than that for pharmaceuticals, which makes exporting far more straightforward – a pellet-format supplement does not face the same new drug classification challenges that our pharmaceutical combination product encounters in foreign markets.”
Internationalisation & the PIC/S Advantage
The modest size of the Taiwanese pharma market (roughly eight billion) – of which generics account for 70 percent of volume but only 20 percent of value, with half of that 20 percent taken up by international generics players – means that domestic generics companies looking for sustainable and sizeable growth must look beyond Taiwan’s borders.
“While we hold a strong position in Taiwan’s OTC segment, the domestic market alone is not sufficient to support long-term growth,” admits Lin, whose company is expanding its presence across the Asia-Pacific region, working through distribution partnerships in Southeast Asia, Hong Kong, Macau, and China, while continuing to collaborate with partners in Japan, Korea, Canada and Europe.
Thankfully, for those considering international expansion, made in Taiwan generics already have a strong reputation for quality abroad. Most importantly, Taiwan has been a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) since 2013. This means that good manufacturing practice (GMP) certificates and inspection results issued by the Taiwan Food and Drug Administration (TFDA) are recognised globally.
“Taiwan’s manufacturing standards are aligned with PIC/S GMP requirements, and that places us at a meaningfully higher quality tier than many lower-cost competitors,” notes Lin. “Clients who prioritise regulatory compliance, product consistency, and supply chain reliability, particularly in highly regulated markets such as Europe, find Taiwan’s quality credentials to be a genuine differentiator. We may not compete on price alone, but we compete very effectively on the combination of quality, regulatory standing, and manufacturing reliability.”
Keeping up to scratch with the demands of PIC/S GMP is, however, no easy task. “It demands significant investment in manufacturing infrastructure and quality systems,” says Ta Fong’s Yeh. Indeed, for those companies already suffering from the aforementioned pricing pressures, attempting to meet PIC/S standards can be a real strain.
“While high standards are essential, alignment between regulatory expectations and practical implementation timelines is critical,” states the TGPA’s Chen. “Without sufficient margin flexibility, companies struggle to absorb rising compliance costs while continuing to invest in quality systems, manufacturing upgrades, and new product development.”
Everest’s Liao agrees, but has a more positive, almost Darwinian take, noting that meeting these standards helps separate the wheat from the chaff, with only the strongest firms surviving.
“Some companies find the requirements too burdensome and step back from them,” she explains. “We have kept going, and I genuinely believe that discipline has made us a better organisation – more consistent, more reliable, and more trusted by the partners we work with. It is also becoming a competitive filter in practice: as regulatory standards continue to rise, those who cannot keep pace exit the market. That creates meaningful space for those who can.”
